- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
AI accurately predicts malignancy on breast ultrasound, cuts down excessive follow-ups and biopsies
Turkey: A recent study published in Academic Radiology has shown the effectiveness of artificial intelligence (AI) to accurately predict malignancy on breast ultrasound based on BI-RADS (Breast Imaging-Reporting and Data System) assessment.
The study revealed that an AI method showed comparable performance to that of radiologists and can help avoid unnecessary biopsies and follow-up exams, which, in turn, can contribute to sustainability in healthcare practices.
“By considering AI-assigned BI-RADS 2 as safe, we could potentially avoid 11% of benign lesion biopsies and 46.2% of follow-ups,” Nilgun Guldogan, Breast Clinic, Acibadem Altunizade Hospital, Istanbul, Turkey, and colleagues reported.
Previous studies have shown increased use of artificial intelligence systems in breast ultrasonography. These studies have shown how AI aids in image interpretation, reduces false-positive cases, and potentially helps decrease the workload of radiologists. Therefore, Dr Guldogan and colleagues evaluated the performance of an AI system for the BI-RADS category assessment in breast masses detected on breast ultrasound.
For this purpose, the researchers analyzed 715 masses detected in 530 patients. Nine breast radiologists and three breast imaging centres of the same institution participated in the study. One radiologist performed an ultrasound and obtained two orthogonal views of each detected lesion. A second radiologist blinded to the patient’s clinical data retrospectively reviewed these images. The images were evaluated by a commercial AI system.
The level of agreement between the AI system and the two radiologists and their diagnostic performance were calculated according to dichotomic BI-RADS category assessment.
The study revealed the following findings:
· The study included 715 breast masses. Of these, 18.75% were malignant, and 81.25% were benign.
· The agreement between AI and the first and second radiologists was moderate statistically in discriminating benign and probably benign from suspicious lesions.
· The sensitivity and specificity of radiologist 1, radiologist 2, and AI were calculated as 98.51% and 80.72%, 97.76% and 75.56%, and 98.51% and 65.40%, respectively.
· For radiologist 1, the positive predictive value (PPV) was 54.10%, the negative predictive value (NPV) was 99.58%, and the accuracy was 84.06%.
· Radiologist 2 achieved a PPV of 47.99%, NPV of 99.32%, and accuracy of 79.72%.
· The AI system exhibited a PPV of 39.64%, NPV of 99.48%, and accuracy of 71.61%.
· None of the lesions categorized as BI-RADS 2 by AI were malignant, while 2 of the lesions classified as BI-RADS 3 by AI were subsequently confirmed as malignant.
· By considering AI-assigned BI-RADS 2 as safe, 11% of benign lesion biopsies and 46.2% of follow-ups could be potentially avoided.
"Artificial intelligence proves effective in predicting malignancy," the researchers wrote, they added, "Integrating it into the clinical workflow has the potential to reduce short-term follow-ups and unnecessary biopsies, which, in turn, can contribute to sustainability in healthcare practices."
Reference:
Guldogan, N., Taskin, F., Icten, G. E., Yilmaz, E., Turk, E. B., Erdemli, S., Parlakkilic, U. T., Turkoglu, O., & Aribal, E. (2023). Artificial Intelligence in BI-RADS Categorization of Breast Lesions on Ultrasound: Can We Omit Excessive Follow-ups and Biopsies? Academic Radiology. https://doi.org/10.1016/j.acra.2023.11.031
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751